IXICO plc (PHYOF)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -4.44 Million USD | 24.18% |
| 2022 | -5.86 Million USD | 28.51% |
| 2021 | -8.2 Million USD | 17.96% |
| 2020 | -9.99 Million USD | -11.67% |
| 2019 | -8.95 Million USD | 12.68% |
| 2018 | -10.25 Million GBP | -216.52% |
| 2017 | -3.23 Million GBP | 20.09% |
| 2016 | -4.05 Million GBP | -109.56% |
| 2015 | -1.93 Million GBP | 41.29% |
| 2014 | -3.29 Million GBP | -24.82% |
| 2013 | -2.63 Million GBP | -819.49% |
| 2012 | -287 Thousand GBP | 90.67% |
| 2011 | -3.07 Million GBP | -177.48% |
| 2010 | -1.1 Million GBP | 71.66% |
| 2009 | -3.91 Million GBP | -143.31% |
| 2008 | -1.6 Million GBP | 28.29% |
| 2007 | -2.24 Million GBP | 62.63% |
| 2006 | -5.99 Million GBP | 48.48% |
| 2005 | -11.64 Million GBP | -114.36% |
| 2004 | -5.43 Million GBP | 3.26% |
| 2003 | -5.61 Million GBP | 38.63% |
| 2002 | -9.14 Million GBP | 32.05% |
| 2001 | -13.45 Million GBP | -158.63% |
| 2000 | -5.2 Million GBP | -92.1% |
| 1999 | -2.7 Million GBP | -18.14% |
| 1998 | -2.29 Million GBP | 63.52% |
| 1997 | -6.28 Million GBP | 31.69% |
| 1996 | -9.2 Million GBP | -38437.5% |
| 1995 | 24 Thousand GBP | 100.0% |
| 1994 | 12 Thousand GBP | 185.71% |
| 1993 | -14 Thousand GBP | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -2.96 Million GBP | 33.34% |
| 2024 Q2 | -2.78 Million USD | 0.0% |
| 2023 Q4 | -4.44 Million USD | 6.82% |
| 2023 Q1 | -5.68 Million GBP | 3.08% |
| 2023 Q3 | -4.76 Million GBP | 14.32% |
| 2023 Q2 | -5.56 Million USD | 2.02% |
| 2023 FY | -4.44 Million USD | 24.18% |
| 2022 Q1 | -7.21 Million GBP | 12.07% |
| 2022 Q2 | -6.9 Million GBP | 4.27% |
| 2022 Q3 | -6.54 Million GBP | 5.21% |
| 2022 FY | -5.86 Million USD | 28.51% |
| 2022 Q4 | -5.86 Million USD | 10.4% |
| 2021 Q3 | -8.52 Million GBP | 3.93% |
| 2021 Q1 | -8.83 Million GBP | 11.58% |
| 2021 FY | -8.2 Million USD | 17.96% |
| 2021 Q4 | -8.2 Million GBP | 3.84% |
| 2021 Q2 | -8.87 Million GBP | -0.44% |
| 2020 Q4 | -9.99 Million GBP | -2.12% |
| 2020 Q1 | -8.82 Million GBP | 1.38% |
| 2020 Q2 | -8.26 Million GBP | 6.4% |
| 2020 FY | -9.99 Million USD | -11.67% |
| 2020 Q3 | -9.78 Million GBP | -18.46% |
| 2019 Q2 | -7.45 Million GBP | 21.56% |
| 2019 FY | -8.95 Million USD | 12.68% |
| 2019 Q3 | -9.22 Million GBP | -23.77% |
| 2019 Q1 | -9.5 Million GBP | -20.86% |
| 2019 Q4 | -8.95 Million GBP | 2.96% |
| 2018 Q2 | -2.69 Million GBP | 25.93% |
| 2018 FY | -10.25 Million GBP | -216.52% |
| 2018 Q4 | -7.86 Million GBP | 24.23% |
| 2018 Q3 | -10.37 Million GBP | -284.41% |
| 2018 Q1 | -3.64 Million GBP | -50.94% |
| 2017 FY | -3.23 Million GBP | 20.09% |
| 2017 Q4 | -2.41 Million GBP | 23.23% |
| 2017 Q3 | -3.14 Million GBP | -12.3% |
| 2017 Q2 | -2.8 Million GBP | 18.85% |
| 2017 Q1 | -3.45 Million GBP | -10.59% |
| 2016 Q3 | -4.14 Million GBP | -30.39% |
| 2016 FY | -4.05 Million GBP | -109.56% |
| 2016 Q2 | -3.18 Million GBP | 32.19% |
| 2016 Q1 | -4.69 Million GBP | -142.56% |
| 2016 Q4 | -3.12 Million GBP | 24.78% |
| 2015 Q2 | -1.95 Million GBP | 35.83% |
| 2015 FY | -1.93 Million GBP | 41.29% |
| 2015 Q3 | -3.04 Million GBP | -55.97% |
| 2015 Q1 | -3.03 Million GBP | 7.74% |
| 2015 Q4 | -1.93 Million GBP | 36.41% |
| 2014 FY | -3.29 Million GBP | -24.82% |
| 2014 Q1 | -6.44 Million GBP | -43.57% |
| 2014 Q4 | -3.29 Million GBP | 0.0% |
| 2014 Q2 | -3.89 Million GBP | 39.63% |
| 2013 FY | -4.49 Million GBP | -819.49% |
| 2013 Q2 | -2.72 Million GBP | 0.0% |
| 2013 Q4 | -4.49 Million GBP | 0.0% |
| 2012 Q4 | -287 Thousand GBP | 0.0% |
| 2012 FY | -287 Thousand GBP | 90.67% |
| 2012 Q2 | -2.73 Million GBP | 0.0% |
| 2011 FY | -3.07 Million GBP | -177.48% |
| 2011 Q2 | -3.87 Million GBP | 0.0% |
| 2011 Q4 | -3.07 Million GBP | 0.0% |
| 2010 Q2 | -26.31 Million GBP | 0.0% |
| 2010 FY | -1.1 Million GBP | 71.66% |
| 2010 Q4 | -1.1 Million GBP | 0.0% |
| 2009 Q4 | -3.91 Million GBP | 0.0% |
| 2009 Q2 | -730 Thousand GBP | 0.0% |
| 2009 FY | -3.91 Million GBP | -143.31% |
| 2008 Q4 | -1.6 Million GBP | 0.0% |
| 2008 FY | -1.6 Million GBP | 28.29% |
| 2008 Q2 | -8.8 Million GBP | 0.0% |
| 2007 FY | -2.24 Million GBP | 62.63% |
| 2007 Q2 | -3.37 Million GBP | 0.0% |
| 2006 Q4 | -5.99 Million GBP | 0.0% |
| 2006 Q2 | -8.07 Million GBP | 0.0% |
| 2006 FY | -5.99 Million GBP | 48.48% |
| 2005 Q4 | -11.64 Million GBP | 0.0% |
| 2005 FY | -11.64 Million GBP | -114.36% |
| 2005 Q2 | -3.67 Million GBP | 0.0% |
| 2004 Q2 | -6.52 Million GBP | 0.0% |
| 2004 Q4 | -5.43 Million GBP | 0.0% |
| 2004 FY | -5.43 Million GBP | 3.26% |
| 2003 Q4 | -5.61 Million GBP | 0.0% |
| 2003 FY | -5.61 Million GBP | 38.63% |
| 2003 Q2 | -60 Thousand GBP | 0.0% |
| 2002 Q2 | -830 Thousand GBP | 0.0% |
| 2002 FY | -9.14 Million GBP | 32.05% |
| 2002 Q4 | -9.14 Million GBP | 0.0% |
| 2001 FY | -13.45 Million GBP | -158.63% |
| 2000 FY | -5.2 Million GBP | -92.1% |
| 1999 FY | -2.7 Million GBP | -18.14% |
| 1998 FY | -2.29 Million GBP | 63.52% |
| 1997 FY | -6.28 Million GBP | 31.69% |
| 1996 FY | -9.2 Million GBP | -38437.5% |
| 1995 FY | 24 Thousand GBP | 100.0% |
| 1994 FY | 12 Thousand GBP | 185.71% |
| 1993 FY | -14 Thousand GBP | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | -339181.45% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 178.688% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 110.386% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -1680.541% |
| Rebus Holdings, Inc. | 305 Thousand USD | 1557.242% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 29.502% |
| Qrons Inc. | 351.42 Thousand USD | 1364.726% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 814.146% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 110.233% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -21678.651% |
| Skye Bioscience, Inc. | -5.72 Million USD | 22.316% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 128.196% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 207.93% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 1206.034% |
| SQZ Biotechnologies Company | -36.23 Million USD | 87.735% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 298.221% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 579.363% |
| Mesoblast Limited | 55.85 Million USD | 107.957% |
| Marizyme, Inc. | 18.56 Million USD | 123.935% |
| Genus plc | 190.6 Million USD | 102.332% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 298.789% |
| Pharming Group N.V. | 109.8 Million USD | 104.048% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 616.668% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 466.145% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 753.616% |
| ContraFect Corporation | -6.02 Million USD | 26.243% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 3401.114% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 484.67% |
| IMV Inc. | 7.67 Million USD | 157.944% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 180.783% |
| MultiCell Technologies, Inc. | 90.04 USD | 4936336.117% |
| ONE Bio Corp. | 9.04 Million USD | 149.166% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -505.548% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 134.332% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 424.904% |
| Q BioMed Inc. | 4.06 Million USD | 209.472% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 114.547% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 541.056% |
| Biomind Labs Inc. | 711.4 Thousand USD | 724.764% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 107.341% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 322.297% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 134.705% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 1335.603% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 3279.156% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 22471.707% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 301.845% |
| GB Sciences, Inc. | 1.74 Million USD | 354.367% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -2318.323% |
| HST Global, Inc. | 96.79 Thousand USD | 4691.848% |
| CSL Limited | 10.52 Billion USD | 100.042% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 2255.296% |
| Halberd Corporation | 144.72 Thousand USD | 3171.142% |
| Enzolytics Inc. | 981.65 Thousand USD | 552.764% |
| Agentix Corp. | 37.63 Thousand USD | 11910.972% |
| Resverlogix Corp. | 6.45 Million USD | 168.898% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -560.327% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.781% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 90.546% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 162.857% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 264.091% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 49.721% |
| AVAX Technologies, Inc. | -5.9 Million USD | 24.709% |
| Zenith Capital Corp. | 10.06 Thousand USD | 44263.225% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.581% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 2317.504% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 286.275% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 2801.729% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -24163.495% |
| Kadimastem Ltd | -253.1 Thousand USD | -1656.046% |
| Helix BioMedix, Inc. | -2.57 Million USD | -72.939% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 121.92% |
| BioStem Technologies, Inc. | 4.47 Million USD | 199.387% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 2308.447% |
| LadRx Corporation | -2.03 Million USD | -118.25% |
| Cell Source, Inc. | 9.23 Million USD | 148.143% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 799.751% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 799.751% |
| NovAccess Global Inc. | 2.17 Million USD | 304.024% |
| Affymax, Inc. | -5.59 Million USD | 20.59% |
| Itoco Inc. | 228.3 Thousand USD | 2046.776% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 3368.343% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 189.663% |
| Mobile Lads Corp. | 484.23 Thousand USD | 1017.863% |
| CytoDyn Inc. | 20.26 Million USD | 121.936% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -686853.168% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -47854.51% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 157.677% |
| SYBLEU INC | 473.71 Thousand USD | 1038.243% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 199.721% |
| International Stem Cell Corporation | 2.59 Million USD | 271.606% |
| Bioxytran, Inc. | 1.89 Million USD | 334.059% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 7221.252% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 303.796% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 229.429% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 151.965% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 675.271% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -255.567% |
| Neutra Corp. | 52.18 Thousand USD | 8616.655% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -78.569% |
| PureTech Health plc | -167.19 Million USD | 97.342% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -1714.799% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 133.623% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 108.103% |
| CSL Limited | 10.52 Billion USD | 100.042% |
| Cellectis S.A. | -43.81 Million USD | 89.857% |